LC
CRSP icon

Lindbrook Capital’s CRISPR Therapeutics CRSP Stock Holding History

Lindbrook Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$885 Sell
26
-26
-50% -$1.1K ﹤0.01% 2499
2024
Q4 		$2.05K Buy
52
+2
+4% +$94 ﹤0.01% 2301
2024
Q3 		$2.35K Buy
50
+18
+56% +$913 ﹤0.01% 2292
2024
Q2 		$1.73K Hold
32
– – ﹤0.01% 2387
2024
Q1 		$2.18K Hold
32
– – ﹤0.01% 2215
2023
Q4 		$2K Buy
32
+27
+540% +$1.49K ﹤0.01% 2260
2023
Q3 		$227 Sell
5
-9
-64% -$465 ﹤0.01% 2623
2023
Q2 		$786 Sell
14
-23
-62% -$1.3K ﹤0.01% 2416
2023
Q1 		$1.67K Buy
37
+4
+12% +$194 ﹤0.01% 2319
2022
Q4 		$1.34K Buy
33
+16
+94% +$849 ﹤0.01% 2391
2022
Q3 		$1K Sell
17
-20
-54% -$1.45K ﹤0.01% 2280
2022
Q2 		$2K Sell
37
-18
-33% -$1.06K ﹤0.01% 1932
2022
Q1 		$3K Buy
55
+35
+175% +$2.2K ﹤0.01% 1802
2021
Q4 		$2K Buy
+20
New +$1.75K ﹤0.01% 1756
2021
Q2 		– Sell
-29
Closed -$4K – 1922
2021
Q1 		$4K Sell
29
-21
-42% -$3.17K ﹤0.01% 1313
2020
Q4 		$8K Buy
50
+40
+400% +$4.73K ﹤0.01% 983
2020
Q3 		$1K Buy
+10
New +$887 ﹤0.01% 1529
2019
Q4 		– Sell
-55
Closed -$2K – 1507
2019
Q3 		$2K Hold
55
– – ﹤0.01% 1248
2019
Q2 		$2K Hold
55
– – ﹤0.01% 1213
2019
Q1 		$1K Hold
55
– – ﹤0.01% 1290
2018
Q4 		$1K Buy
+55
New +$1.91K ﹤0.01% 1241

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lindbrook Capital's CRSP Position: Q1 2025 in Review

Lindbrook Capital reduced its CRISPR Therapeutics (CRSP) stake by 50% in Q1 2025, selling an estimated $1.1K and leaving 26 shares worth $885. The position accounts for ﹤0.01% of the portfolio, ranked #2499.

Lindbrook Capital first reported a position in CRSP in Q4 2018 and has held it in 21 quarters since. The position peaked at $8K in Q4 2020. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

  • Lindbrook Capital held 26 shares of CRISPR Therapeutics worth $885 as of Q1 2025.
  • Lindbrook Capital sold 26 CRISPR Therapeutics shares in Q1 2025, an estimated $1.1K.
  • CRISPR Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2499 holding.
  • Lindbrook Capital first reported a position in CRISPR Therapeutics in Q4 2018 and has held it in 21 quarters since.
  • Lindbrook Capital's CRISPR Therapeutics position peaked at $8K in Q4 2020.
  • 396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.